INTRODUCTION The treatment of choice for Atypical Hemolytic Uremic Syndrome (aHUS) is the monoclonal antibody eculizumab. The objective of this study was to assess the efficacy and safety of eculizumab in a cohort of kidney transplant patients suffering from aHUS. METHODS Description of the prospective cohort of all the patients primarily treated with eculizumab after transplantation and divi...

14. Teixeira L, Debourdeau P, Zammit C, Estival JL, Pavic M, Colle B. Gemcitabine-induced thrombotic microangiopathy. Presse Med. 2002;31:740—2. 15. Phelan PJ, Liew A, Magee C. A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke. Ren Fail. 2009;31:743—4. 16. Goodnough LT, Saito H, Manni A, Jones PK, Pearson...

Atypical hemolytic uremic syndrome is a rare disease associated with genetic or acquired defects in complement regulation which frequently leads to renal failure. Disease often recurs early after kidney transplantation, leading to a rapid irreversible loss of function. Extrarenal features, such as hemolysis and thrombocytopenia, may not always occur, and diagnosis is made by demonstrating the c...

Enterohemorrhagic Escherichia coli (EHEC) produce ribosome-inactivating Shiga toxins (Stx1, Stx2) responsible for development of hemolytic uremic syndrome (HUS) and acute kidney injury (AKI). Some patients show complement activation during EHEC infection, raising the possibility of therapeutic targeting of complement for relief. Our juvenile nonhuman primate (Papio baboons) models of endotoxin-...